Author's posts
FDA clears Boston Scientific device for atrial fibrillation
The FDA has granted approval to a device made by Boston Scientific to treat atrial fibrillation, the company announced in a Jan. 31 news release.
Tuberculosis cases are on the rise in California, reversing decades-long trend
Santa Clara County in Northern California saw a 19% increase in tuberculosis cases between 2022 and 2023. It’s a trend that is also happening statewide, The Mercury News reported Jan. 30.
Tuberculosis cases are on the rise in California, reversing decades-long trend
Santa Clara County in Northern California saw a 19% increase in tuberculosis cases between 2022 and 2023. It’s a trend that is also happening statewide, The Mercury News reported Jan. 30.
Hospitals could get boost from rising Medicare Advantage use
Increasing Medicare Advantage spending could be a bright spot for hospitals’ finances.
Hospitals could get boost from rising Medicare Advantage use
Increasing Medicare Advantage spending could be a bright spot for hospitals’ finances.
Former Trump official to lead Oracle's EHR business
Oracle has tapped the former head of CMS under the Trump administration to lead its electronic health records division, Bloomberg Law reported Jan. 31.
Former Trump official to lead Oracle's EHR business
Oracle has tapped the former head of CMS under the Trump administration to lead its electronic health records division, Bloomberg Law reported Jan. 31.
HCA now operates 186 hospitals, nearly 50k beds
Nashville, Tenn.-based HCA Healthcare is now operating 186 hospitals and 49,588 total licensed beds, up three hospitals and 279 beds from the third quarter, 2023, according to its financial report released Jan. 30.
HCA now operates 186 hospitals, nearly 50k beds
Nashville, Tenn.-based HCA Healthcare is now operating 186 hospitals and 49,588 total licensed beds, up three hospitals and 279 beds from the third quarter, 2023, according to its financial report released Jan. 30.
23andMe far from spitting distance to big healthcare aims: WSJ
Despite its ambitions to become a major healthcare player, 23andMe’s valuation is down 98% from its peak and has never turned a profit, according to reporting from The Wall Street Journal.
